GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology.

Our proprietary vaccine technology has been developed through multi-year collaborations with Emory University, the U.S. National Institutes of Health (NIH), and the U.S. Centers for Disease Control and Prevention (CDC).  Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.

Our current development programs are focused on preventive and therapeutic vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses (Ebola, Sudan, Marburg and Lassa), Zika virus and malaria. We also have initiated programs to develop therapeutic vaccines to treat chronic Hepatitis B (HBV) infections, human papilloma virus (HPV) and MUC1-positive cancer types in combination with other approaches (e.g. checkpoint inhibitors) to achieve a high cure rate. We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases and we intend to pursue expansion of our pipeline products.

We know our work could affect the lives of millions worldwide, and we invite you to join our efforts.